NCT05340764View on ClinicalTrials.gov

Safety of Reduced Infliximab Infusion Time

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Infliximab

Infliximab is an effective and commonly used medication to treat patients with IBD

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT05340764 - Safety of Reduced Infliximab Infusion Time | Biotech Hunter | Biotech Hunter